Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

Shares of Agios Pharmaceuticals (AGIO) were up 5.2% on Jan 3, after management reported that the phase III ENERGIZE study, evaluating orally-administered mitapivat in certain thalassemia patients, achieved its primary and key secondary endpoints.A total of 194 adult participants with non-transfusion-dependent (NTD) alpha- or beta-thalassemia were enrolled in the ENERGIZE study. These patients were randomized into two treatment arms — 130 patients who received a 100mg dose of mitapivat and the remaining 64 p ...